Arovella Therapeutics (FRA:E4NA) Dividends per Share : €0.00 (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics Dividends per Share?

Arovella Therapeutics's dividends per share for the six months ended in Dec. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2024 was 0.00. As of today, Arovella Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Arovella Therapeutics Dividends per Share Historical Data

The historical data trend for Arovella Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Dividends per Share Chart

Arovella Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Dividends per Share

Get a 7-Day Free Trial

Arovella Therapeutics Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Arovella Therapeutics's Dividends per Share

For the Biotechnology subindustry, Arovella Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arovella Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Arovella Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

Arovella Therapeutics (FRA:E4NA) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Arovella Therapeutics's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.001
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Arovella Therapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

ALA:Australia

Address

84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.arovella.com

Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Arovella Therapeutics Headlines

No Headlines